{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:16Z","timestamp":1791486856349,"version":"4.3.4"},"reference-count":65,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia & Lymphoma"],"published-print":{"date-parts":[[2016,5,3]]},"DOI":"10.3109\/10428194.2016.1161185","type":"journal-article","created":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T14:03:03Z","timestamp":1460037783000},"page":"1021-1032","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":165,"title":["Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy"],"prefix":"10.3109","volume":"57","author":[{"given":"Maria-Elisabeth","family":"Goebeler","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]},{"name":"Department of Internal Medicine II, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Bargou","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken, University Hospital W\u00fcrzburg","place":["W\u00fcrzburg, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,4,6]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708875"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0107"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.12.011"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00190.x"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.4623"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2392"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12245"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.8.4224"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.19.6.1211"},{"key":"e_1_3_2_18_1","first-page":"2005","article-title":"Tumour MHC class I downregulation and immunotherapy (Review).","volume":"10","author":"Bubenik J.","year":"2003","unstructured":"Bubenik J. Tumour MHC class I downregulation and immunotherapy (Review). Oncol Rep. 2003;10:2005\u20132008.","journal-title":"Oncol Rep"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.2741\/1575"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh194"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.004"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2013.03.029"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.15.7021"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10557"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902943077"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010"},{"key":"e_1_3_2_28_1","first-page":"10","article-title":"Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.","volume":"1","author":"Kufer P","year":"2001","unstructured":"Kufer P, Zettl F, Borschert K, et\u00a0al. Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs. Cancer Immun. 2001;1:10.","journal-title":"Cancer Immun"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03554-3"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.8.4397"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-007-0298-z"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-003-0496-2"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2008.11.014"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1159\/000075685"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2007.12.007"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.184"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.559668"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-485623"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-36"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80418-5"},{"key":"e_1_3_2_46_1","first-page":"169","article-title":"PI3K as a target for therapy in haematological malignancies.","volume":"347","author":"Khwaja A.","year":"2010","unstructured":"Khwaja A. PI3K as a target for therapy in haematological malignancies. Curr Top Microbiol Immunol. 2010;347:169\u2013188.","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25462"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545"},{"key":"e_1_3_2_49_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase 1 study.","author":"Goebeler ME","year":"2016","unstructured":"Goebeler ME, Knop S, Viardot A, et\u00a0al. Bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase 1 study. J Clin Oncol. 2016; pii: JCO591586 [Epub ahead of print].","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_50_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of bispecific T-cell engager (BiTE\u00ae) antibody blinatumomab in relapsed\/refractory diffuse large B cell lymphoma.","author":"Viardot A","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, et\u00a0al. Phase 2 study of bispecific T-cell engager (BiTE\u00ae) antibody blinatumomab in relapsed\/refractory diffuse large B cell lymphoma. Blood 2016; pii: blood-2015-06-651380 [Epub ahead of print].","journal-title":"Blood"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037093"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.7270"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.379.379"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.239"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.100073"},{"key":"e_1_3_2_59_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.V124.21.2292.2292","article-title":"Phase 1\/2 study in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment.","volume":"124","author":"von Stackelberg A","year":"2014","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, et\u00a0al. Phase 1\/2 study in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) receiving blinatumomab treatment. Blood. 2014;124:61.","journal-title":"Blood"},{"key":"e_1_3_2_60_1","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1182\/blood.V124.21.3703.3703","article-title":"Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia.","volume":"124","author":"Gore L","year":"2014","unstructured":"Gore L, Locatelli F, Zugmaier G, et\u00a0al. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Blood. 2014;124:3703.","journal-title":"Blood"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00082"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000043"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-400515"},{"key":"e_1_3_2_65_1","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood.V124.21.2291.2291","article-title":"Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients.","volume":"124","author":"Duell J","year":"2014","unstructured":"Duell J, Dittrich M, Bedke T, et\u00a0al. Crucial role of regulatory T cells in predicting the outcome of the T cell engaging antibody blinatumomab in relapsed and refractory B precursor ALL patients. Blood. 2014;124:2291.","journal-title":"Blood"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxu089"}],"container-title":["Leukemia & Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2016.1161185","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.3109\/10428194.2016.1161185","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.3109\/10428194.2016.1161185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:06:04Z","timestamp":1784711164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.3109\/10428194.2016.1161185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,6]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5,3]]}},"alternative-id":["10.3109\/10428194.2016.1161185"],"URL":"https:\/\/doi.org\/10.3109\/10428194.2016.1161185","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}